Published in J Med Genet on June 01, 2005
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
The link between the GBA gene and parkinsonism. Lancet Neurol (2012) 1.80
Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med (2011) 1.71
Glucocerebrosidase is shaking up the synucleinopathies. Brain (2014) 1.50
Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem (2009) 1.39
The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep (2010) 1.28
Lipid defect underlies selective skin barrier impairment of an epidermal-specific deletion of Gata-3. J Cell Biol (2006) 1.28
Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci U S A (2012) 1.15
Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics (2009) 1.14
A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol (2011) 1.12
Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem (2008) 1.10
Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis (2010) 1.08
Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. Mol Genet Metab (2009) 1.06
The role of saposin C in Gaucher disease. Mol Genet Metab (2012) 1.02
Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts. J Inherit Metab Dis (2012) 0.95
Gaucher disease: insights from a rare Mendelian disorder. Discov Med (2012) 0.95
Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells. PLoS One (2013) 0.91
Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. Am J Hematol (2012) 0.90
Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Rev Proteomics (2016) 0.83
Type 2 Gaucher disease occurs in Ashkenazi Jews but is surprisingly rare. Blood Cells Mol Dis (2009) 0.82
Optimal therapy in Gaucher disease. Ther Clin Risk Manag (2010) 0.82
Laboratory and genetic evaluation of Gaucher disease. Wien Med Wochenschr (2010) 0.81
Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases. Metab Brain Dis (2013) 0.81
Quantitative high-throughput analysis of synthetic genetic interactions in Caenorhabditis elegans by RNA interference. Genomics (2008) 0.75
Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet (2000) 4.12
Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet (2009) 4.02
A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med (1987) 2.77
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology (2006) 2.65
Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience (2007) 2.55
Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat (2000) 2.43
Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. Hum Mol Genet (2000) 2.43
Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med (1995) 2.39
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab (2003) 2.29
Parkinsonism among Gaucher disease carriers. J Med Genet (2004) 2.24
Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology (2006) 2.19
Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals. Proc Natl Acad Sci U S A (1988) 2.10
Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome 1q21: implications for Gaucher disease. Genome Res (1997) 2.06
Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature (1992) 2.04
Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab (2001) 1.74
Detection of polyglutamine expansion in a new acidic protein: a candidate for childhood onset schizophrenia? Mol Psychiatry (1999) 1.70
GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology (2011) 1.69
The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology (2004) 1.63
The neurogenetics of mucolipidosis type IV. Neurology (2002) 1.62
Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis (2000) 1.61
Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease. J Clin Invest (1994) 1.58
Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke (2001) 1.56
Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation (2001) 1.46
Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis (2005) 1.44
Evidence for neuroaxonal injury in patients with proteolipid protein gene mutations. Neurology (2001) 1.42
Lack of an association between a dopamine-4 receptor polymorphism and attention-deficit/hyperactivity disorder: genetic and brain morphometric analyses. Mol Psychiatry (1998) 1.41
Glycogen storage disease types I and II: treatment updates. J Inherit Metab Dis (2007) 1.39
Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology (2003) 1.36
Hypomyelination with atrophy of the basal ganglia and cerebellum: follow-up and pathology. Neurology (2007) 1.34
Mapping of the mucolipidosis type IV gene to chromosome 19p and definition of founder haplotypes. Am J Hum Genet (1999) 1.32
Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol (2000) 1.32
Peripheral and central hypomyelination with hypogonadotropic hypogonadism and hypodontia. Neurology (2006) 1.28
The nucleotide sequence of the luxA and luxB genes of Xenorhabdus luminescens HM and a comparison of the amino acid sequences of luciferases from four species of bioluminescent bacteria. Biochem Biophys Res Commun (1990) 1.27
Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis (2009) 1.26
The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr (2001) 1.25
Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum Gene Ther (1998) 1.25
Epidermal sphingomyelins are precursors for selected stratum corneum ceramides. J Lipid Res (2000) 1.24
Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology (1998) 1.22
Clinical features of and recent advances in therapy for Fabry disease. JAMA (2000) 1.21
Cholinergic therapy for Down's syndrome. Lancet (1999) 1.19
Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci U S A (1999) 1.19
Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet (2001) 1.17
Genotypic heterogeneity and phenotypic variation among patients with type 2 Gaucher's disease. Pediatr Res (1998) 1.16
Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation. Pediatr Res (2000) 1.16
Prenatal lethality of a homozygous null mutation in the human glucocerebrosidase gene. Am J Med Genet (1997) 1.14
Five patients with a recently described novel leukoencephalopathy with brainstem and spinal cord involvement and elevated lactate. Neuropediatrics (2004) 1.14
Foamy cells with oligodendroglial phenotype in childhood ataxia with diffuse central nervous system hypomyelination syndrome. Acta Neuropathol (2000) 1.14
The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology (1993) 1.13
Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis (2003) 1.13
Human tyrosine hydroxylase (TH) genomic fragment (pHGTH4) identifies a PstI polymorphism. Nucleic Acids Res (1988) 1.10
The E326K mutation and Gaucher disease: mutation or polymorphism? Clin Genet (2002) 1.09
Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis (2010) 1.08
Hydrops fetalis: lysosomal storage disorders in extremis. Adv Pediatr (1999) 1.06
Enzyme replacement therapy in Fabry disease. J Inherit Metab Dis (2001) 1.02
Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease. Mol Genet Metab (2000) 1.02
55-base pair deletion in certain patients with Gaucher disease complicates screening for common Gaucher alleles. Am J Med Genet (1996) 1.01
Neuronopathic forms of Gaucher's disease. Baillieres Clin Haematol (1997) 1.00
Chromosome 22q11.2 interstitial deletions among childhood-onset schizophrenics and "multidimensionally impaired". Am J Med Genet (1998) 1.00
Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology (2006) 1.00
Differentiation of the glucocerebrosidase gene from pseudogene by long-template PCR: implications for Gaucher disease. Am J Hum Genet (1996) 1.00
Mucolipidosis type IV: characteristic MRI findings. Neurology (1998) 1.00
Quantitative analysis of epidermal innervation in Fabry disease. Neurology (1999) 0.99
Proton magnetic resonance spectroscopic imaging in childhood ataxia with diffuse central nervous system hypomyelination. Neurology (1995) 0.97
Mucolipidosis IV consists of one complementation group. Proc Natl Acad Sci U S A (1999) 0.97
Oral and craniofacial findings in Fabry's disease: a report of 13 patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2001) 0.96
Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder. Neurology (2008) 0.96
Two novel polymorphic sequences in the glucocerebrosidase gene region enhance mutational screening and founder effect studies of patients with Gaucher disease. Hum Genet (1999) 0.95
A monozygotic twin pair with highly discordant Gaucher phenotypes. Blood Cells Mol Dis (2010) 0.95
Cardiac Pathology in Glycogen Storage Disease Type III. JIMD Rep (2012) 0.95
Type 2 gaucher disease: an expanding phenotype. Mol Genet Metab (1999) 0.94
Dubowitz syndrome: a defect in the cholesterol biosynthetic pathway? Am J Med Genet (1999) 0.93
Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease. Brain (2006) 0.92
Lysosomal inclusions in gastric parietal cells in mucolipidosis type IV: a novel cause of achlorhydria and hypergastrinemia. Am J Surg Pathol (1999) 0.92
Type 2 Gaucher disease with hydrops fetalis in an Ashkenazi Jewish family resulting from a novel recombinant allele and a rare splice junction mutation in the glucocerebrosidase locus. Mol Genet Metab (1998) 0.91
Inhibition of denitrification by uncouplers of oxidative phosphorylation. Biochemistry (1978) 0.91
A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse. Mol Chem Neuropathol (1995) 0.90
Proton magnetic resonance spectroscopic imaging in the clinical evaluation of patients with Niemann-Pick type C disease. J Neurol Neurosurg Psychiatry (1998) 0.90
The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease. J Med Genet (1996) 0.90
Gustin from human parotid saliva is carbonic anhydrase VI. Biochem Biophys Res Commun (1998) 0.89
Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp Hematol (1999) 0.89
Gene rearranagement on 1q21 introducing a duplication of the glucocerebrosidase pseudogene and a metaxin fusion gene. Hum Genet (2000) 0.89
Dominant inheritance of sialuria, an inborn error of feedback inhibition. Am J Hum Genet (2001) 0.89
Molecular diagnostics for myelin proteolipid protein gene mutations in Pelizaeus-Merzbacher disease. Am J Hum Genet (1992) 0.89
Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate. Am J Med Genet (1999) 0.88
Congenital ichthyosis preceding neurologic symptoms in two sibs with type 2 Gaucher disease. Am J Med Genet (1995) 0.88
Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology (1999) 0.87
Golli-MBP copy number analysis by FISH, QMPSF and MAPH in 195 patients with hypomyelinating leukodystrophies. Ann Hum Genet (2006) 0.87
Emerging therapies for glycogen storage disease type I. Trends Endocrinol Metab (2009) 0.86
Acute hydrocephalus in nonketotic hyperglycemia. Neurology (2000) 0.86